ZLAB - 1 Hot Growth Stock to Buy Hand Over Fist Before It Blasts Off
2023-03-26 07:45:00 ET
There's a good chance that Zai Lab 's (NASDAQ: ZLAB) stock will make a journey into the stratosphere in the next few years, and that means growth-hungry investors should consider loading up on its shares, and soon.
Whereas other mid-cap biotechs of roughly its size might be struggling to get their first medicine out the door, Zai Lab already has several on the market, and it soon probably will have even more thanks to a bazaar's worth of late-stage programs barreling toward commercialization. Let's explore what that could mean for shareholders and examine how it manages to be so prolific.
Zai Lab's rocket fuel is its pipeline, which could yield it more than eight new drug launches within the next three years, in addition to the four cancer treatments it already has on the market. Between the launches and its existing products, management is anticipating that it will be profitable before the start of 2026. That's good, because its $1 billion in cash should be enough to last it through much of 2025 but not beyond, given its total operating expenses of $545.3 million last year.
For further details see:
1 Hot Growth Stock to Buy Hand Over Fist Before It Blasts Off